(1-异丁基哌啶-4-基)甲醇 | 915923-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (1-异丁基哌啶-4-基)甲醇
• 英文名称: (1-Isobutylpiperidin-4-YL)methanol
• 英文别名: [1-(2-methylpropyl)piperidin-4-yl]methanol
• CAS: 915923-25-0
• 化学式: C₁₀H₂₁NO
• mdl: MFCD08691501
• 分子量: 171.28
• InChiKey: SNXAUSJVVABUEI-UHFFFAOYSA-N

物化性质

• 沸点：
  243.0±13.0 °C(Predicted)
• 密度：
  0.915±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

文献信息

• AMPK ACTIVATORS
  申请人：Kallyope, Inc.

  公开号：US20220002317A1

  公开（公告）日：2022-01-06

  This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

  这份披露至少部分针对AMPK激活剂，用于治疗与AMPK相关的疾病或疾病。在某些实施例中，该疾病或疾病与肠-脑轴有关。在某些实施例中，该疾病或疾病与有漏肠屏障引起的全身感染和炎症有关。在某些实施例中，AMPK激活剂是肠道限制性化合物。在某些实施例中，AMPK激活剂是激动剂、超激动剂、全激动剂或部分激动剂。
• DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：EP3715343A1

  公开（公告）日：2020-09-30

  Disclosed are a diphenylaminopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition comprising these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.

  本发明公开了一种对蛋白酪氨酸激酶具有抑制作用的二苯基氨基嘧啶化合物、其药学上可接受的盐、晶体形式、原药、代谢物、水合物、溶解物、立体异构体或同位素衍生物、包含这些化合物的药物组合物以及这些化合物的制备和使用方法。该化合物具有式（I）所代表的结构，可用于治疗ALK介导的癌症相关症状，如非小细胞肺癌、乳腺癌、神经肿瘤、食道癌、软组织癌、淋巴瘤或白血病。
• PD-1/PD-L1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10710986B2

  公开（公告）日：2020-07-14

  Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

  本研究公开了式（I）化合物、单独使用所述化合物或将其与其他制剂结合使用的方法以及所述化合物用于治疗癌症的组合物。
• Dianilinopyrimidine compound for inhibiting kinase activity
  申请人：Shenzhen Targetrx, Inc.

  公开号：US11254696B2

  公开（公告）日：2022-02-22

  Disclosed are a dianilino pyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.

  本发明公开了一种对蛋白酪氨酸激酶具有抑制作用的二苯胺基嘧啶化合物、其药学上可接受的盐、晶体形式、原药、代谢物、水合物、溶解物、立体异构体或同位素衍生物、含有这些化合物的药物组合物以及这些化合物的制备和使用方法。该化合物具有式（I）所代表的结构，可用于治疗ALK介导的癌症相关症状，如非小细胞肺癌、乳腺癌、神经肿瘤、食道癌、软组织癌、淋巴瘤或白血病。
• PD-1/PD-L1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190270727A1

  公开（公告）日：2019-09-05

  Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.